pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

961 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1850Endpoints1433Fierce Biotech751BioSpace741BioPharma Dive544raps245onclive165fda recalls
therapy area
allOncology12794Rare Disease3303Immunology2978Cardiology2837Hematology2278Pulmonology2221Vaccines
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 2h agoDealPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 13h agoCRLNegative↗ source
← prev
page 1 of 39
next →
118
fda medwatch113
globenewswire health73
fda press59
1837
Psychiatry & CNS1227
Ophthalmology1125
Endocrinology & Metabolism794
Pain787
Nephrology779
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 6h agoDealPositive↗ source
  • Roche breast cancer pill cleared by FDA
    Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.
    BioPharma Dive · 1h ago↗ source
  • CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
    CG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
    BioPharma Dive · 1d agoPositive readoutPositive↗ source
  • FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancer
    Summit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
    BioPharma Dive · 1d agoRegulatoryNegative↗ source
  • J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolio
    Johnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug Discoveries
    Scientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…
    BioPharma Dive · 1d agoNeutral↗ source
  • Clinical AI pilots stall due to organizational environment, not technology
    Clinical teams are increasingly using artificial intelligence to draft regulatory paperwork, assist data review, shape trial design and interpret complex evidence. The technology is proving its val…
    BioPharma Dive · 1d agoNeutral↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi
    Seawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…
    BioPharma Dive · 1d agoDealPositive↗ source
  • FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissioner
    The FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
    raps · 1d agoRegulatoryNeutral↗ source
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thickets
    Industry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…
    raps · 1d agoRegulatoryNeutral↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 1d agoPositive↗ source
  • Experts discuss AI applications and challenges in regulatory conformity assessments
    At a recent RAPS AI in Regulatory Conference in Barcelona, a panel of experts examined how artificial intelligence is being adopted in conformity assessment processes. Participants noted that noti…
    raps · 1d agoRegulatoryNeutral↗ source
  • Australian regulator seeks feedback on adding unique device IDs to medical device free‑sale certificates
    Australia’s Therapeutic Goods Administration (TGA) announced it is reviewing whether to include unique device identification (UDI) details on certificates of free sale that accompany medical device…
    raps · 1d agoRegulatoryNeutral↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 4d agoApprovalPositive↗ source
  • Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series A
    Venture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…
    BioPharma Dive · 4d agoDealPositive↗ source
  • Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitor
    Windward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
    BioPharma Dive · 4d agoDealPositive↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…
    raps · 4d agoRegulatoryNegative↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The FDA sent warning letters to three active pharmaceutical ingredient manufacturers based in China. Two firms were cited for refusing the agency's requests for records, while the third was found…
    raps · 4d agoRegulatoryNeutral↗ source
  • FDA faces over 1,000 vacant positions as staffing shortage strains pharma oversight
    The FDA currently has more than a thousand open jobs, reflecting a deep staffing shortfall that began after a large wave of departures last year. The agency lost 1,343 employees at its CBER and CD…
    BioPharma Dive · 5d agoNegative↗ source
  • FDA pauses voucher program as Eli Lilly's GLP-1 weight-loss drug cleared in China; experts see AI aid for device regulation
    The U.S. Food and Drug Administration announced it is shelving the commissioner's voucher program, effectively pausing the incentive that speeds up review of certain products. Eli Lilly secured ap…
    raps · 5d agoRegulatoryNeutral↗ source
  • EMA seeks industry input on draft guideline for biomarker-guided therapy approvals
    The European Medicines Agency has published a draft guideline that details the information required for approving medicines that use biomarkers to select patients. The agency is opening a public c…
    raps · 5d agoRegulatoryNeutral↗ source